Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GALT $11.61 1.3300 +12.94%
PVCT $2.32 0.2100 +9.95%
SRNE $10.55 0.9000 +9.33%
AMBI $6.94 0.5300 +8.27%
CYTR $3.23 0.2300 +7.67%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

INO $2.52 -0.1500 -5.62%
THLD $3.83 -0.1900 -4.73%
INFI $10.15 -0.4500 -4.25%
NYMX $5.04 -0.2199 -4.18%
KPTI $31.09 -1.3100 -4.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

Obama Administration Reverses Proposed Cut to Medicare Plans

(Washington Post/Wonkblog) Apr 7, 2014 - Medicare has reversed proposed payment cuts to private heath plans in the popular Medicare Advantage program for the second straight year amid strong pushback from health insurers and Capitol Hill.
read article (free registration required) 

CORRECTION - Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120 Pan-RAF Inhibitor Created and Developed in Collaboration with Eli Lilly

(Deciphera Pharmaceuticals) Apr 7, 2014 - (Correction replaces previous link posted in OBR daily yesterday) Deciphera Pharmaceuticals today announced the initiation of a Phase 1 clinical trial of its pan-RAF inhibitor LY3009120 (DP-4978), under development in collaboration with Eli Lilly.
read corporate press release 

Stand Up To Cancer and the Farrah Fawcett Foundation Announce New HPV Translational Research Team Grant

(AACR) Apr 7, 2014 - Research efforts will investigate approaches to develop novel immune therapies for HPV-associated cancers; HPV and Anal Cancer Foundation contributes to support of team.
read press release 

New SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Announced

(AACR) Apr 7, 2014 - Stand Up To Cancer (SU2C), The Lustgarten Foundation, and the Fox Family Cancer Research Funding Trust, along with the American Association for Cancer Research (AACR), SU2C’s Scientific Partner, announced the formation of a Dream Team dedicated to pancreatic cancer research during a press event today at the AACR Annual Meeting 2014, held here April 5-9.
read press release 

American Association for Cancer Research Inaugurates New Leadership at 2014 Annual Meeting

(AACR) Apr 7, 2014 - The American Association for Cancer Research (AACR) welcomes Carlos L. Arteaga, M.D., as president of the organization for 2014-2015.
read press release 

AACR 2014: Where ‘Meaningful Advances’ Against Cancer Begin

(City of Hope) Apr 5, 2014 - With more than 6,000 findings being presented over a five-day period at the 105th AACR annual meeting, the amount of information can seem overwhelming.
read article 

Puma Falls on Disappointing Breast-Cancer Drug Results

(Bloomberg) Apr 7, 2014 - Puma Biotechnology Inc. plunged the most ever after a company-sponsored study found only a suggestion of benefit with its experimental drug for breast cancer in one group of women whose tumors are driven by a specific protein.
read article 

Pfizer Shares Drop Despite Positive Test for Breast-cancer Drug

(MarketWatch/Health Exchange blog) Apr 7, 2014 - Pfizer Inc. dropped 3% — a relatively large amount for a big pharma firm — on Monday despite seemingly positive test results for its breast-cancer treatment palbociclib.
read article 

Gene, Immune Therapy Help Cancer War

(San Diego Union-Tribune) Apr 7, 2014 - The war on cancer is getting some potent reinforcements, including a potentially broad-spectrum new weapon and genetically engineered immune cells with improved cancer-fighting abilities, speakers said at a major cancer research conference held this week in San Diego.
read article 

CancerCare® Announces Oncology Leader Patricia J. Goldsmith as CEO

(CancerCare) Apr 7, 2014 - Patricia Goldsmith to lead CancerCare, 70-year-old national nonprofit for people coping with cancer.
read press release 

CEO Roundtable on Cancer Launches the Project Data Sphere Initiative, A New Data Sharing and Analytic Platform for Cancer Patient Benefit

(Yahoo! Finance) Apr 8, 2014 - Project Data Sphere, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), announced today the launch of a new data sharing platform (, with the goal of advancing research to improve the lives of cancer patients and their families around the world.
read article 

N-of-One Selected by Dartmouth-Hitchcock Norris Cotton Cancer Center to Provide Clinical Interpretation for Molecular Diagnostics Program

(Yahoo! Finance) Apr 8, 2014 - N-of-One, Inc. today announced an agreement with Dartmouth-Hitchcock Medical Center in Lebanon, NH to provide clinical interpretation for Dartmouth-Hitchcock’s Next-Generation Sequencing tests as part of Norris Cotton Cancer Center’s comprehensive molecular diagnostics and treatment program.
read article 

Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS® (Brentuximab Vedotin) in Key Countries

(MarketWatch) Apr 8, 2014 - Seattle Genetics, Inc. will receive milestone payments from Takeda Pharmaceutical Company Limited totaling $6 million as a result of achieving the first commercial sale of ADCETRIS (brentuximab vedotin) in three key countries in Takeda’s territories outside of the European Union and Japan, consisting of Australia, South Korea and Mexico.
read article 

Turkish Drug Exporter Ozay Draws U.S. Scrutiny

(Wall Street Journal) Apr 7, 2014 - U.S. officials say they have traced much of the illicit cancer medication that has turned up in U.S. doctors' offices in recent years to Ozay Pharmaceutical, a small Turkish company.
read article (paid subscription required) 

Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis®

(MarketWatch) Apr 7, 2014 - Myriad Genetics, Inc. today announced that it has submitted the first module of a premarket approval (PMA) application to the Food and Drug Administration (FDA) for the use of BRACAnalysis® testing as a companion diagnostic with olaparib.
read article 

Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data

(Pharmacyclics) Apr 8, 2014 - Pharmacyclics, Inc. today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label Phase III RESONATE(TM) study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICA(TM) (ibrutinib) versus ofatumumab in 391 patients with CLL or SLL, who had received at least one prior therapy.
read corporate press release 

Ambit Announces Initiation Of Quizartinib QUANTUM-R Phase 3 Trial

(Reuters) Apr 8, 2014 - Ambit Biosciences today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.
read article 

Not So Fast: Dividing Cells Use a “Speed Limit” to Avoid Genetic Mistakes

(MSKCC/OnCancer blog) Apr 8, 2014 - One of the main functions of the nucleus is to protect the cell’s chromosomes, or DNA molecules, and preserve their genetic information when the cell divides.
read article 

For Teen Girls, Fruits and Veggies Linked to Lower Risk of Breast Condition

(Reuters Health) Apr 7, 2014 - Teenage girls who eat more colorful fruits and vegetables are less likely to develop benign breast disease as young adults, according to a new study.
read article 

Circumcision Could Prevent Prostate Cancer… if It’s Performed After the Age of 35

(University of Montreal News) Apr 7, 2014 - Researchers at the University of Montreal and the INRS-Institut-Armand-Frappier have shown that men circumcised after the age of 35 were 45% less at risk of later developing prostate cancer than uncircumcised men.
read press release 

Look for Cancer, and Find It

(New York Times/Well blog) Apr 7, 2014 - Mammography has become a fighting word in recent years, with some researchers questioning its value and others staunchly defending it.
read article 

For Good and Ill, Immune Response to Cancer Cuts Both Ways

(UC San Diego) Apr 7, 2014 - The difference between an immune response that kills cancer cells and one that conversely stimulates tumor growth can be as narrow as a “double-edged sword,” report researchers.
read press release 

Genomic Analysis Yields Abnormalities Associated with Targeted Treatments in Rare and Poor Prognosis Cancers

(Rutgers CINJ) Apr 7, 2014 - Research from Rutgers Cancer Institute of New Jersey shows genomic profiling identifies genomic alterations in tumors that can be associated with targeted therapies in the treatment of rare and poor prognosis cancers.
read press release 

AACR 2014: Thwarting Drug-resistant Lung Cancer with a Novel Compound

(City of Hope) Apr 4, 2014 - A group of City of Hope researchers have identified and synthesized a novel compound — called COH-SR4 — that is effective against drug-resistant lung cancer.
read article 

AACR 2014: Father’s Age at Birth May Affect Daughter’s Cancer Risk

(City of Hope) Apr 7, 2014 - A team of City of Hope researchers, lead by Yani Lu, Ph.D., explored this relationship and found that a parent’s age at birth, particularly a father’s age, may affect the adult-onset cancer risk for daughters — especially for breast cancer.
read article